Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer.
Clinically, high expression levels of EP2, phosphorylated GYS1, and HIF-1α in tumor tissues correlated with poor therapeutic response to osimertinib, and elevated serum concentrations of inflammatory cytokines in NSCLC patients, suggesting that EP2 serves as a critical regulator linking metabolic reprogramming and infl...